BPC-157: What the Research Does and Doesn’t Show

BPC-157 (Body Protective Compound-157) is one of the most-discussed peptides in recovery research. It is also one of the most over-marketed. If you have spent any time reading about peptides online, you have probably encountered confident claims that BPC-157 heals tendons, ligaments, the gut, and the brain, written as if they were settled medical science.

They are not. This article explains what BPC-157 is, what the published research has and has not examined, and where it stands with regulators, so you can read those claims critically.

What BPC-157 actually is

BPC-157 is a synthetic 15-amino-acid peptide first characterized in the 1990s by Predrag Sikiric and colleagues at the University of Zagreb. It was derived from a partial sequence of a larger protein originally isolated from human gastric juice — hence the name “Body Protective Compound.” Its full sequence is GEPPPGKPADDAGLV.

BPC-157 is not FDA-approved for any use in the United States. The FDA has stated that it does not consider BPC-157 a lawful dietary supplement ingredient. The World Anti-Doping Agency has listed BPC-157 as prohibited for athletes since 2022.

What the preclinical research reports

The preclinical literature is unusually large for an unapproved compound — more than 200 published animal studies, concentrated in the Sikiric laboratory and collaborating groups, with some work from other institutions.

These are animal and laboratory findings, not human results. Researchers have studied BPC-157 in animal models of tendon and ligament injury, gastric injury, inflammatory bowel disease, and brain injury. Benefit in people has not been established.

Proposed mechanisms, also from laboratory and animal research, involve several signaling systems, including VEGF and nitric oxide pathways. The number of different mechanisms reported has itself drawn skepticism from researchers, since compounds said to act through many pathways are harder to characterize.

Why human evidence remains limited

No large, well-controlled human trials have established BPC-157 as safe or effective for any condition. Published human data consist of small early-phase studies and case reports, which cannot establish effectiveness or safety.

Part of the reason is economic. BPC-157 is a fragment of a naturally occurring protein and is difficult to protect with a patent, so there is little commercial incentive to fund the large trials required for FDA approval. This is a recurring problem in peptide research.

The result is a compound with a sizable animal literature and very little high-quality human evidence. Animal findings frequently fail to translate to people, so the gap matters.

Regulatory status

BPC-157 is not FDA-approved. Its eligibility for pharmacy compounding has changed several times. In July 2026, FDA’s Pharmacy Compounding Advisory Committee recommended it for the 503A Bulks List, but the FDA has not completed that process, and an advisory committee vote does not make it FDA-approved. The Tide does not offer BPC-157. Our article on the legal status of BPC-157 walks through the details.

Safety: what is and isn’t known

Human safety has not been established. Long-term effects in people are unknown. Researchers have raised theoretical concerns about use in people with active or recent cancer, because of BPC-157’s reported effects on blood vessel growth in animal studies. Products sold online as “research peptides” are not regulated for human use and may vary in purity, dose, and sterility.

Reading claims about BPC-157 critically

When you encounter claims about BPC-157, a few questions help separate research from marketing:

Is the claim based on animal or human evidence? Most BPC-157 findings come from animal studies. A claim presented as a proven human benefit is overstating the research.

Who conducted the research? Much of the literature comes from a small number of research groups. Independent replication is an important test of any finding.

What does the FDA say? BPC-157 is not FDA-approved, and the FDA does not consider it a lawful supplement ingredient. Any source that describes it as approved, proven, or risk-free is not giving you the full picture.

The honest summary

BPC-157 has a sizable body of animal research and very limited human evidence. It is not FDA-approved, its human safety has not been established, and its regulatory status is still evolving. It is a useful case study in the difference between preclinical findings and proven medicine — a distinction worth applying to any compound marketed with more confidence than the evidence supports.